DUBLIN, Ohio, Aug. 10, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced its efforts to commercialize and broaden access to over-the-counter rapid COVID-19 tests through partnerships with Abbott and Quidel Corporation ("Quidel").
Cardinal Health will leverage its expansive distribution network to support broad access to Quidel's QuickVue® At-Home OTC COVID-19 Test and Abbott's BinaxNOW™ COVID-19 Antigen Self-Test, which allow consumers to easily perform tests for the virus without a prescription.
"Rapid over-the-counter tests will be pivotal in supporting the safe and sustained reopening of our country, especially as we see a rise in cases due to the Delta variant," said Chris Kerski, senior vice president and general manager, Cardinal Health Laboratory Products. "Because we offer a full suite of solutions for COVID-19 testing, as well as vaccine transport and storage, Cardinal Health has been helping organizations and communities determine the best solutions for bringing their populations safely back out of the home since the pandemic began. We're proud to say we now offer these over-the-counter products as part of our holistic laboratory products portfolio."
With the addition of rapid at-home tests, Cardinal Health's laboratory products portfolio can now support customized testing and surveillance programs for workplaces, the travel and hospitality industry, and schools with comprehensive solutions that include at-home tests, rapid on-site testing, PCR (molecular testing) and on-site or at-home specimen collection.
"Cardinal Health's safe reopening offerings and broad channel presence will play a key role in widening access to testing," said Douglas Bryant, president and chief executive officer, Quidel. "Quidel and Cardinal Health have collaborated closely since the start of the pandemic to serve the country with these COVID-19 testing solutions. On March 17, 2020, just days after the U.S. declared COVID-19 a national emergency, we received emergency use authorization of our high throughput PCR testing platform and, that very same day, announced that we partnered exclusively with Cardinal Health to distribute it rapidly and broadly. This was essential early-on in the global fight against the virus – and the work didn't stop there."
Bryant added, "Cardinal Health and Quidel continued working together on a massive distribution push to get our Sofia® SARS rapid antigen assay out to the largest health system in the U.S. – and this latest distribution partnership is another critical step forward in Quidel's efforts to democratize access to our testing solutions, including our QuickVue® At-Home OTC COVID-19 antigen."
COVID-19 OTC rapid tests allow employers, schools and individuals to easily implement screening and surveillance testing programs to identify both symptomatic and asymptomatic infections. While the effort to vaccinate more Americans continues, these programs will also remain a vital piece in mitigating the spread of COVID-19 as new variants like Delta emerge and with the potential for the virus to reemerge seasonally.
"As the most widely used and studied rapid COVID-19 antigen tests in the U.S., BinaxNOW has helped communities, schools, workplaces and families quickly identify infectious people and help stop the spread of the virus," said Andrea Wainer, executive vice president, Rapid and Molecular Diagnostics, Abbott. "Partnering with Cardinal Health widens the distribution of our over-the-counter self-tests to more organizations around the country, providing people with answers quickly and in the comfort of their own homes."
In addition to providing COVID-19 OTC rapid tests, Cardinal Health Laboratory Products provides consumables, including swabs and viral transport media, as well as customizable specimen collection kits to support the testing needs of laboratories and decentralized testing sites. It also provides a range of solutions for COVID-19 vaccine storage from the time it is manufactured until it's administered. In addition, the company offers comprehensive testing solutions for respiratory viruses and other infectious diseases ranging from core lab molecular testing to rapid point-of-care platforms.
To read more about Cardinal Health Laboratory Products and its response to COVID-19, click here. For more information on Cardinal Health's safe reopening offerings, click here.
About Cardinal Health Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With 50 years in business, operations in more than 40 countries and approximately 48,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.
The BinaxNOW™ COVID-19 Antigen Self-Test has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization. It has been authorized only for the detection of proteins from SARSCoV-2, not for any other viruses or pathogens, and are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. BinaxNOW COVID-19 Antigen Self-Test should be performed twice in 3 days, at least 36 hours apart.
The QuickVue® At-Home OTC COVID-19 Test is only for use under the Food and Drug Administration's Emergency Use Authorization. The QuickVue® At-Home OTC COVID-19 Test has not been FDA cleared or approved. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.